- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04582695
Early Intervention Following Sexual Assault
May 7, 2026 updated by: Medical University of South Carolina
Integrated Early Intervention for Alcohol Use Disorder and Posttraumatic Stress Disorder Following Sexual Assault
This study is for women who have experienced a sexual assault in the past six weeks and use alcohol.
The research involves completing a five week behavioral treatment for stress and alcohol use.
Participants will complete surveys during visits.
Participants may also be asked to complete brief daily assessments on their smart phones.
Study Overview
Status
Completed
Conditions
Detailed Description
The primary objective of the proposed Stage IA/IB study is to establish feasibility of an integrated cognitive-behavioral intervention for reducing alcohol use disorder (AUD) and posttraumatic stress disorder (PTSD) symptoms among women who experienced a sexual assault within the past six weeks.
The intervention will be tested in an open label trial to make final modifications to evaluate feasibility, acceptability, and preliminary efficacy of the five to six week integrated intervention with standardized repeated measures during a one-month follow-up.
Next, a pilot randomized controlled trial will be conducted among 54 recent sexual assault victims to evaluate feasibility and preliminary efficacy in reducing AUD severity and PTSD symptoms.
Ecological momentary assessments (EMA) will be used to assess alcohol use, craving, and affect during the five-week treatment phase.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Female; any race or ethnicity; age 18 to 65 years old.
- Sexual assault that occurred within the past 12 months.
- Subjects must be able to comprehend English.
- A score of 3 or greater on the Alcohol Use Disorders Identification Test (AUDIT-C) screen.
- A score of 31 or greater on the Posttraumatic Stress Disorder Checklist for the Diagnostic and Statistical Manual of Mental Disorders (PCL-5). Subjects may also meet criteria for an alcohol use disorder, previous history of posttraumatic stress disorder, mood disorder (except bipolar affective disorder, see Exclusion Criteria) or other anxiety disorders (panic disorder, agoraphobia, social phobia, generalized anxiety disorder, or obsessive-compulsive disorder). The inclusion of subjects with affective and other anxiety disorders is essential because of the marked frequency of the co-existence of mood and other anxiety disorders among patients with AUD and PTSD (Norman et al., 2018; Zinzow et al., 2012). Subjects may meet the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for another substance use disorder if AUD is the primary substance of choice.
- Must consent to complete all treatment and follow-up visits.
Exclusion Criteria:
- Lack of any memory of the sexual assault
- Subjects meeting the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for a history of or current psychotic, bipolar, dissociative identify disorder, or a current eating disorder, as the study protocol may be therapeutically insufficient.
- Subjects experiencing significant withdrawal symptoms, as evidence by a score of 10 or more on the Clinical Institute Withdrawal Assessment of Alcohol (CIWA). These subjects will be referred for clinical detoxification and may be re-assessed for study eligibility after medically supervised detoxification has been completed.
- Individuals considered an immediate suicide risk, with current suicidal ideation and intent.
- Individuals who attempted suicide in the past month. These individuals will be referred directly for treatment.
- Individuals on psychotropic medications must be stabilized on it for at least two weeks prior to beginning the study.
- Any other medical or psychiatric conditions that the investigators believe may compromise the individual's ability to safely participate in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Written Exposure Therapy
|
Participants will receive 5 to 6 weeks of written exposure therapy, which involves writing about their experience of sexual assault for 30 minutes.
|
|
Experimental: Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder
|
Participants will receive 5 to 6 weeks of an integrated behavioral therapy that address posttraumatic stress disorder and alcohol use disorder.
Sessions will be 60 minutes in length.
It will include written exposure therapy, which involves writing about their experience of sexual assault for 30 minutes.
In addition, they will receive 20 minutes of intervention focused on cognitive behavioral therapy for alcohol use disorder which involves learning skills to cope with alcohol cravings and behavior (e.g., challenging thoughts, problem solving).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Percent Drinking Days on The Time Line Follow-Back
Time Frame: Participants will report on drinking during the 30 days prior to initiation of the study, and every day until study completion completion of study visits, approximately six weeks.
|
The Time Line Follow Back (TLFB) will be used to assess heavy drinking in the past 30-days.
This calendar-assisted interview yielded estimates in terms of the number of standard drinks consumed daily in the past 30 days used to obtain retrospective self-report of alcohol use by using a calendar and other memory prompts to stimulate recall.
|
Participants will report on drinking during the 30 days prior to initiation of the study, and every day until study completion completion of study visits, approximately six weeks.
|
|
Change in number of standard drinks per drinking day on The Time Line Follow-Back
Time Frame: Participants will report on drinking during the 30 days prior to initiation of the study, and ever day until completion of study visits, approximately six weeks.
|
The Time Line Follow Back (TLFB) will be used to assess heavy drinking in the past 30-days and use.
This calendar-assisted interview yielded estimates in terms of the number of standard drinks consumed daily in the past 30 days used to obtain retrospective self-report of alcohol use by using a calendar and other memory prompts to stimulate recall.
|
Participants will report on drinking during the 30 days prior to initiation of the study, and ever day until completion of study visits, approximately six weeks.
|
|
Change in Posttraumatic Stress Disorder Symptoms on The Posttraumatic Stress Disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders (PCL-5)
Time Frame: Baseline and after completion of study visits, approximately six weeks.
|
Participants will be asked to complete the 20-item Posttraumatic Checklist for Diagnostic and Statistical Manual of Mental Disorders (PCL-5) to measure traumatic stress symptoms corresponding with the Diagnostic and Statistical Manual of Mental Disorders -5 PTSD criteria.
Items are rated on a five-point Likert scale ranging from 0 (Not at all) to 4 (Extremely) with higher scores indicating greater traumatic stress symptoms.
Total scores will be used.
|
Baseline and after completion of study visits, approximately six weeks.
|
|
Change in Posttraumatic Stress Disorder Symptoms on The Clinician-Administered Posttraumatic Stress Disorder Scale for the Diagnostic and Statistical Manual of Mental Disorders
Time Frame: Baseline and after completion of study visits, approximately six weeks.
|
The Clinician-Administered Posttraumatic Stress Disorder Scale for the Diagnostic and Statistical Manual of Mental Disorders (CAPS-5) is the gold standard in Posttraumatic Stress Disorder (PTSD) assessment.
It is a structured 30-minute interview that can be used to diagnosis PTSD.
Items focus on symptom presence, onset and duration of symptoms, subjective distress, impact on functioning, and symptom improvement.
|
Baseline and after completion of study visits, approximately six weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Depression Symptoms on The Patient Health Questionnaire-9.
Time Frame: Baseline and after completion of study visits, approximately six weeks.
|
The Patient Health Questionnaire-9 is a widely used self-report measure for attitudes and symptoms of depression.
The PHQ-9 includes 9 self-report items.
Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 27.
A total score of 0-4 is considered minimal range, 5-9 is mild, 10-14 is moderate, 15-19 is moderately severe, and 20 or more is severe.
|
Baseline and after completion of study visits, approximately six weeks.
|
|
Change in Anxiety Symptoms on The Beck Anxiety Inventory
Time Frame: Baseline and after completion of study visits, approximately six weeks.
|
The Beck Anxiety Inventory (BAI) assesses symptoms of anxiety via 21-item self-report.
The BAI reliability discriminates anxiety-disordered from non-anxiety disordered patients and demonstrates excellent convergence with related anxiety scales.
The values for each item are summed yielding an overall or total score for all 21 symptoms that can range between 0 and 63 points.
A total score of 0 - 7 is interpreted as a "Minimal" level of anxiety; 8 - 15 as "Mild"; 16 - 25 as "Moderate", and; 26 - 63 as "Severe".
|
Baseline and after completion of study visits, approximately six weeks.
|
|
Change in Percent Days Using Substances on The Time Line Follow-Back
Time Frame: Participants will report on substance use during the 30 days prior to initiation of the study, and every day until study completion completion of study visits, approximately six weeks.
|
The Time Line Follow-Back will be used to assess illicit substance use in the past 30-days.
This calendar-assisted interview yielded estimates in terms of self-report of substance use by using a calendar and other memory prompts to stimulate recall.
|
Participants will report on substance use during the 30 days prior to initiation of the study, and every day until study completion completion of study visits, approximately six weeks.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 15, 2020
Primary Completion (Actual)
February 23, 2026
Study Completion (Actual)
February 23, 2026
Study Registration Dates
First Submitted
September 28, 2020
First Submitted That Met QC Criteria
October 5, 2020
First Posted (Actual)
October 9, 2020
Study Record Updates
Last Update Posted (Actual)
May 11, 2026
Last Update Submitted That Met QC Criteria
May 7, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Trauma and Stressor Related Disorders
- Mental Disorders
- Substance-Related Disorders
- Chemically-Induced Disorders
- Alcohol-Related Disorders
- Stress Disorders, Traumatic
- Alcoholism
- Stress Disorders, Post-Traumatic
- Organic Chemicals
- Behavior Therapy
- Psychotherapy
- Behavioral Disciplines and Activities
- Alcohols
- Ethanol
- Cognitive Behavioral Therapy
Other Study ID Numbers
- 00099114
- 1K23AA028055 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Use Disorder
-
Technische Universität DresdenCharite University, Berlin, Germany; Central Institute of Mental Health, MannheimRecruitingAlcoholism | Methamphetamine-dependence | Substance Use Disorders | Cocaine Use Disorder | Alcohol Use Disorder (AUD) | Cannabis Use Disorder | Amphetamine Use DisorderGermany
-
Washington State UniversityRecruitingNicotine Use Disorder | Alcohol Use Disorder (AUD)United States
-
Indiana UniversityPatient-Centered Outcomes Research InstituteRecruitingAdolescent | Alcohol Use | Mild Alcohol Use Disorder | Mild Substance Use DisorderUnited States
-
University of North Carolina, Chapel HillCompletedAlcohol Use Disorder, Mild | Alcohol Use Disorder, ModerateUnited States
-
University of BernRecruitingAlcohol Use Disorder (AUD) | Substance Use Disorder (SUD) | Cocaine Use Disorder (CUD)Switzerland
-
Université du Québec à Trois-RivièresCompletedAlcohol Use, Unspecified | Alcohol Use Disorder, MildCanada
-
University of Wisconsin, MadisonNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Not yet recruitingAlcohol Use Disorder | Alcohol Use Disorder (AUD)United States
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Technische Universität DresdenCharite University, Berlin, Germany; Central Institute of Mental Health, MannheimRecruitingAlcoholism | Substance Use Disorders | Alcohol Use Disorder (AUD)Germany
-
University of Notre DameNational Institute on Alcohol Abuse and Alcoholism (NIAAA)RecruitingAlcohol Use | Opioid Use Disorder | Alcohol Use Disorder | Opioid UseUnited States
Clinical Trials on Written Exposure Therapy
-
Palo Alto Veterans Institute for ResearchCompletedWritten Exposure Therapy | Imaginal Exposure TherapyUnited States
-
Columbia UniversityNational Center for PTSDTerminatedStroke | PTSD | Acute Coronary Syndrome | Cardiac Arrest | TIAUnited States
-
University of Texas Southwestern Medical CenterTexas Child Mental Healthcare Consortium (TCMHCC)Active, not recruitingPost-Traumatic Stress Disorder in Adolescence | PTSD - Post Traumatic Stress Disorder | PTSD and Trauma-related Symptoms | Pregnancy and PTSDUnited States
-
University of ManitobaCompletedPost Traumatic Stress DisorderCanada
-
Jesse McCannTerminatedStress Disorders, Post-Traumatic | Sexual Assault and RapeUnited States
-
University of Colorado, BoulderUniversity of Colorado, DenverCompletedLymphoproliferative Disorders | Anxiety | Metastatic Cancer | Solid Tumor Cancer | Post-traumatic Stress Symptoms | Fear of Cancer ProgressionUnited States
-
St. Joseph's Healthcare HamiltonRecruitingPosttraumatic Stress DisorderCanada
-
RANDBoston University; Clinical Directors NetworkActive, not recruiting
-
St. Joseph's Healthcare HamiltonNot yet recruitingPosttraumatic Stress Disorder (PTSD) | Borderline Personality Disorder (BPD)Canada
-
University of North Carolina, Chapel HillUS Department of Veterans Affairs; Foundation of Hope, North CarolinaCompletedPost-traumatic Stress DisorderUnited States